KR102714554B1 - 신규한 치환된 크산틴 유도체 - Google Patents

신규한 치환된 크산틴 유도체 Download PDF

Info

Publication number
KR102714554B1
KR102714554B1 KR1020207000260A KR20207000260A KR102714554B1 KR 102714554 B1 KR102714554 B1 KR 102714554B1 KR 1020207000260 A KR1020207000260 A KR 1020207000260A KR 20207000260 A KR20207000260 A KR 20207000260A KR 102714554 B1 KR102714554 B1 KR 102714554B1
Authority
KR
South Korea
Prior art keywords
trpc5
compound
mmol
disorder
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000260A
Other languages
English (en)
Korean (ko)
Other versions
KR20200030048A (ko
Inventor
카이 겔라크
크리스티안 아이크마이어
아킴 자우어
슈테판 유스트
버트랜드 엘. 체널드
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
하이드라 바이오사이언시스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하, 하이드라 바이오사이언시스, 엘엘씨 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20200030048A publication Critical patent/KR20200030048A/ko
Application granted granted Critical
Publication of KR102714554B1 publication Critical patent/KR102714554B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207000260A 2017-07-11 2018-07-06 신규한 치환된 크산틴 유도체 Active KR102714554B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
EP17180721.7 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (2)

Publication Number Publication Date
KR20200030048A KR20200030048A (ko) 2020-03-19
KR102714554B1 true KR102714554B1 (ko) 2024-10-10

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000260A Active KR102714554B1 (ko) 2017-07-11 2018-07-06 신규한 치환된 크산틴 유도체

Country Status (32)

Country Link
US (1) US10329292B2 (enExample)
EP (1) EP3652176B1 (enExample)
JP (1) JP7114702B2 (enExample)
KR (1) KR102714554B1 (enExample)
CN (1) CN110997675B (enExample)
AR (1) AR112448A1 (enExample)
AU (1) AU2018299824B2 (enExample)
CA (1) CA3066922A1 (enExample)
CL (1) CL2020000056A1 (enExample)
CO (1) CO2019015102A2 (enExample)
CY (1) CY1125014T1 (enExample)
DK (1) DK3652176T3 (enExample)
EA (1) EA039526B1 (enExample)
ES (1) ES2903268T3 (enExample)
HR (1) HRP20220029T1 (enExample)
HU (1) HUE057600T2 (enExample)
IL (1) IL271799B (enExample)
LT (1) LT3652176T (enExample)
MX (1) MX394089B (enExample)
MY (1) MY200797A (enExample)
PE (1) PE20200861A1 (enExample)
PH (1) PH12020500079A1 (enExample)
PL (1) PL3652176T3 (enExample)
PT (1) PT3652176T (enExample)
RS (1) RS62826B1 (enExample)
SA (1) SA519410851B1 (enExample)
SG (1) SG11201912168TA (enExample)
SI (1) SI3652176T1 (enExample)
SM (1) SMT202200013T1 (enExample)
TW (1) TWI801398B (enExample)
UA (1) UA124793C2 (enExample)
WO (1) WO2019011802A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231208B2 (en) 2018-03-05 2025-01-23 Gfb (Abc), Llc Imidazodiazepinediones and methods of use thereof
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok
EP3894409B1 (en) 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
EP4037680A4 (en) * 2019-10-04 2023-10-04 Goldfinch Bio, Inc. BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSSCLEROSIS AND DIABETIC KIDNEY DISEASE
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2024164818A1 (zh) 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DE602007012254D1 (de) * 2006-07-14 2011-03-10 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-methylbenzyl)oxyü-2-ä(2r)-2-methylpiperazin-1-ylü-6,7-dihydro-5h-cyclopentaäbüpyridin
LT2970303T (lt) * 2013-03-15 2017-07-25 Hydra Biosciences, Inc. Pakeistieji ksantinai ir jų panaudojimo metodai
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016041845A1 (en) 2014-09-17 2016-03-24 Boehringer Ingelheim International Gmbh Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
PH12020500079A1 (en) 2020-10-05
SG11201912168TA (en) 2020-01-30
AU2018299824B2 (en) 2022-06-16
IL271799A (en) 2020-02-27
CN110997675A (zh) 2020-04-10
AR112448A1 (es) 2019-10-30
MX2020000402A (es) 2020-08-17
TW201908318A (zh) 2019-03-01
CA3066922A1 (en) 2019-01-17
SMT202200013T1 (it) 2022-03-21
PL3652176T3 (pl) 2022-04-04
NZ759728A (en) 2024-11-29
HUE057600T2 (hu) 2022-05-28
US20190016722A1 (en) 2019-01-17
CL2020000056A1 (es) 2020-06-12
US10329292B2 (en) 2019-06-25
SI3652176T1 (sl) 2022-04-29
BR112019025611A2 (pt) 2020-06-16
SA519410851B1 (ar) 2023-02-26
MX394089B (es) 2025-03-24
KR20200030048A (ko) 2020-03-19
RS62826B1 (sr) 2022-02-28
ES2903268T3 (es) 2022-03-31
EA039526B1 (ru) 2022-02-07
LT3652176T (lt) 2022-02-25
AU2018299824A1 (en) 2019-12-19
CY1125014T1 (el) 2023-03-24
JP7114702B2 (ja) 2022-08-08
JP2020526591A (ja) 2020-08-31
MY200797A (en) 2024-01-16
IL271799B (en) 2022-08-01
DK3652176T3 (da) 2022-01-17
EP3652176A1 (en) 2020-05-20
EA202090270A1 (ru) 2020-04-24
PE20200861A1 (es) 2020-08-25
CO2019015102A2 (es) 2020-05-15
WO2019011802A1 (en) 2019-01-17
UA124793C2 (uk) 2021-11-17
EP3652176B1 (en) 2021-12-15
TWI801398B (zh) 2023-05-11
CN110997675B (zh) 2022-06-07
PT3652176T (pt) 2022-01-13
HRP20220029T1 (hr) 2022-04-15

Similar Documents

Publication Publication Date Title
KR102714554B1 (ko) 신규한 치환된 크산틴 유도체
EP3894409B1 (en) Substituted xanthine derivatives
EP3894410B1 (en) Substituted xanthine derivatives
HK40025200A (en) Substituted xanthine derivatives
HK40025200B (en) Substituted xanthine derivatives
BR112019025611B1 (pt) Compostos derivados de xantina substituídos e sais dos mesmos
EA043969B1 (ru) Замещенные ксантиновые производные

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601